Physician profile
Ben Behnam
NPI 1720278534
$5,775.29
in general payments reported to CMS, 2019-2025
30 companies · $565 in 2025
The $565 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $348 · 2021: $231 · 2022: $610 · 2023: $1,121 · 2024: $2,395 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497 · Travel and Lodging: $1,489 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.24 |
| Travel and Lodging | $1,488.67 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,766.31 | 2023-2024 | Puraply Wound Matrix, Apligraf, Novachor |
| Janssen Biotech, INC. | $897.25 | 2020-2025 | Tremfya |
| Pfizer INC. | $513.88 | 2019-2025 | |
| Abbvie INC. | $331.97 | 2019-2025 | Botox |
| Lilly USA, LLC | $329.04 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $301.83 | 2019-2025 | Winlevi |
| Genzyme Corporation | $224.56 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $185.28 | 2022-2023 | Dupixent |
| Leo Pharma INC. | $162.72 | 2019-2024 | Adbry |
| Galderma Laboratories, L.P. | $157.52 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.93 | 2019-2023 | Arazlo |
| Arcutis Biotherapeutics, INC. | $99.40 | 2023-2024 | Zoryve |
| Ucb, INC. | $92.89 | 2021-2025 | Bimzelx, Cimzia |
| Strata Skin Sciences, INC. | $92.15 | 2020-2022 | |
| Dermavant Sciences, INC. | $77.97 | 2023-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.71 | 2022-2023 | Otezla |
| Journey Medical Corporation | $37.64 | 2022 | |
| Almirall LLC | $37.22 | 2022-2023 | Seysara |
| Epi Health, LLC | $33.82 | 2019 | |
| Organon LLC | $30.27 | 2025 | Vtama |
| Surgenex LLC | $28.38 | 2025 | Renograft, Pellograft, Surgraft |
| Mimedx Group, INC. | $27.94 | 2024 | |
| Integra Lifesciences Corporation | $22.91 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Novartis Pharmaceuticals Corporation | $18.58 | 2023 | |
| Mindera Corp | $17.52 | 2025 | |
| Merck Sharp & Dohme LLC | $17.44 | 2019 | |
| Revance Therapeutics, INC. | $15.00 | 2025 | Daxxify |
| Paratek Pharmaceuticals, INC. | $14.85 | 2022 | |
| Celgene Corporation | $13.70 | 2019 | |
| Incyte Corporation | $13.61 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Behnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.